In the past several decades, identification of epidermal growth factor receptor (EGFR) mutations has become a critical part of treatment planning in advanced lung cancer and particularly in non-small cell lung cancer (NSCLC) cases11. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.